Evidence map›Paper›PMID 36170461›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.

Urvi A Shah, Kylee H Maclachlan, Andriy Derkach, Meghan Salcedo, Kelly Barnett, Julia Caple, Jenna Blaslov, Linh Tran, Amanda Ciardiello, Miranda Burge and 28 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06987708 (Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers Associated With Monoclonal Gammopathy of Unknown Significance), which is not on this map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06987708 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers Associated With Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Myeloma (SM): A Prospective Intervention Pilot Study

TypeinterventionalSponsorHackensack Meridian HealthRan2026 to 2028Enrolled67ConditionsMonoclonal Gammopathy of Uncertain Significance, Smoldering MyelomaArmsThe Multimodal Lifestyle Intervention
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Risk factors for multiple myeloma and its precursor diseases.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 6 institutions in 1 country.

Urvi A Shah *Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-8419-1091
Kylee H Maclachlan *Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7873-4854
Andriy DerkachDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-2178-8493
Meghan SalcedoMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4010-1829
Kelly BarnettMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-8389-0341
Julia CapleMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6310-6334
Jenna BlaslovMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2871-457X
Linh TranMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-8827-6471
Amanda CiardielloMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9463-8168
Miranda BurgeMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-5236-4514
Tala ShekarkhandMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-1404-4771
Peter AdintoriBone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7099-1143
Justin CrossDonald B. and Catherine C. Marron Cancer Metabolism Center, Sloan Kettering Institute, New York, New York.ORCID 0000-0002-6356-057X
Matthew J PiankoDepartment of Medicine, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-9295-9750
Kinga HosszuDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-1190-1491
Devin McAvoyDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7807-6775
Sham MailankodyMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2815-9561
Neha KordeMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-5538-4318
Malin HultcrantzMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-9045-6495
Hani HassounMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2036-1749
Carlyn R TanMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7922-2594
Sydney X LuDepartment of Medicine, Division of Hematology, Stanford University School of Medicine, Palo Alto, California.ORCID 0000-0002-2217-1674
Dhwani PatelMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-0566-4773
Benjamin DiamondMyeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida.ORCID 0000-0002-8638-9365
Gunjan ShahDepartment of Medicine, Weill Cornell Medical College, New York, New York.ORCID 0000-0002-9977-0456
Michael ScordoDepartment of Medicine, Weill Cornell Medical College, New York, New York.ORCID 0000-0002-9484-0240
Oscar LahoudDepartment of Medicine, Weill Cornell Medical College, New York, New York.ORCID 0000-0002-3291-286X
David J ChungDepartment of Medicine, Weill Cornell Medical College, New York, New York.ORCID 0000-0003-0469-839X
Heather LandauDepartment of Medicine, Weill Cornell Medical College, New York, New York.ORCID 0000-0002-3152-1189
Saad Z UsmaniMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-5484-8731
Sergio GiraltDepartment of Medicine, Weill Cornell Medical College, New York, New York.ORCID 0000-0003-1944-5053
Ying TaurInfectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6601-8284
C Ola LandgrenMyeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida.ORCID 0000-0001-6485-4839
Gladys BlockNutritionQuest, Berkeley, California.ORCID 0000-0001-6722-930X
Torin BlockNutritionQuest, Berkeley, California.ORCID 0000-0001-5399-1950
Jonathan U PeledDepartment of Medicine, Weill Cornell Medical College, New York, New York.ORCID 0000-0002-4029-7625
Marcel R M van den BrinkDepartment of Medicine, Weill Cornell Medical College, New York, New York.ORCID 0000-0003-0696-4401
Alexander M LesokhinMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9321-702X
Memorial Sloan Kettering Cancer Center · USAdvanced BioNutrition (United States) · USSylvester Comprehensive Cancer Center · USKettering University · USPalo Alto University · USUniversity of Michigan · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
T LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SCHEINBERG, DAVID A · 1985 to 2023
$59.0M
Clinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0M
Research Education CoreP30AG024824 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Neil Alexander · 2004 to 2026
$29.2M
Thymic and Peripheral Aspects of T Cell Aging and RejuvenationP01AG052359 · NIA · UNIVERSITY OF ARIZONA · PI Jarrod Dudakov · 2017 to 2026
$23.5M
Targeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Simon N. Powell · 2020 to 2026
$16.3M
MSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3M
Mutographs differentiating the racial and temporal incidence of multiple myelomaR01CA249981 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MORGAN, GARETH JOHN · 2021 to 2025
$5.6M
The role of intestinal microbiota in graft-versus-host diseaseR01CA228308 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Philip L Lorenzi, Marcel R M van den Brink · 2018 to 2026
$5.2M
The role of autophagy gene Atg16L1 in allogeneic hematopoietic stem cell transplantation - Resubmission - 1R01HL123340 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CADWELL, KEN HASHIGIWA, VAN DEN BRINK, MARCEL R M · 2015 to 2022
$5.2M
NCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR001873NCI NIH HHS K12 CA184746NCI NIH HHS K12 CA226330NCI NIH HHS P01 CA023766NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA046592NCI NIH HHS P50 CA247749NCI NIH HHS R01 CA228308NCI NIH HHS R01 CA228358NCI NIH HHS R01 CA249981NCI NIH HHS R25 CA203650NHLBI NIH HHS K08 HL143189NHLBI NIH HHS R01 HL123340NHLBI NIH HHS R01 HL147584NIA NIH HHS P01 AG052359NIA NIH HHS P30 AG024824
6 · The paper itself

Abstract

purposeSustained minimal residual disease (MRD) negativity is associated with long-term survival in multiple myeloma. The gut microbiome is affected by diet, and in turn can modulate host immunity, for example through production of short-chain fatty acids including butyrate. We hypothesized that dietary factors affect the microbiome (abundance of butyrate-producing bacteria or stool butyrate concentration) and may be associated with multiple myeloma outcomes. EXPERIMENTAL

designWe examined the relationship of dietary factors (via a food frequency questionnaire), stool metabolites (via gas chromatography-mass spectrometry), and the stool microbiome (via 16S sequencing - α-diversity and relative abundance of butyrate-producing bacteria) with sustained MRD negativity (via flow cytometry at two timepoints 1 year apart) in myeloma patients on lenalidomide maintenance. The Healthy Eating Index 2015 score and flavonoid nutrient values were calculated from the food frequency questionnaire. The Wilcoxon rank sum test was used to evaluate associations with two-sided P < 0.05 considered significant.

resultsAt 3 months, higher stool butyrate concentration (P = 0.037), butyrate producers (P = 0.025), and α-diversity (P = 0.0035) were associated with sustained MRD negativity. Healthier dietary proteins, (from seafood and plants), correlated with butyrate at 3 months (P = 0.009) and sustained MRD negativity (P = 0.05). Consumption of dietary flavonoids, plant nutrients with antioxidant effects, correlated with stool butyrate concentration (anthocyanidins P = 0.01, flavones P = 0.01, and flavanols P = 0.02).

conclusionsThis is the first study to demonstrate an association between a plant-based dietary pattern, stool butyrate production, and sustained MRD negativity in multiple myeloma, providing rationale to evaluate a prospective dietary intervention.

Indexed as

Multiple MyelomaButyratesDiet, HealthyDiet, VegetarianHumansNeoplasm, ResidualButyrates

Identifiers

PMID36170461
PMCPMC9722533
OpenAlexW4297513407

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.